Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at HC Wainwright

Key Points

• HC Wainwright has reaffirmed a "buy" rating for Arrowhead Pharmaceuticals (NASDAQ: ARWR) with a target price of $80.00, indicating a potential upside of 118.94% from its current price.
• Arrowhead Pharmaceuticals has reported a net loss of ($1.26) EPS for the last quarter, missing analysts' expectations, alongside a revenue of $27.77 million which also fell short of estimates.
• Insider trading activity has seen James C. Hamilton selling 20,000 shares for $700,000, which marks an 8.62% decrease in his ownership of the company’s stock over the last three months.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $80.00 target price on the biotechnology company's stock. HC Wainwright's price target suggests a potential upside of 118.94% from the company's current price.

A number of other research firms have also issued reports on ARWR. TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, July 28th. Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a research report on Saturday, September 27th. Chardan Capital reissued a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Finally, B. Riley raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $43.14.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR opened at $36.54 on Wednesday. The stock has a fifty day moving average price of $25.37 and a two-hundred day moving average price of $18.50. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. The firm has a market cap of $5.05 billion, a P/E ratio of -28.55 and a beta of 1.13. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $39.42.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same period in the previous year, the business earned ($1.38) EPS. Research analysts forecast that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 20,000 shares of the firm's stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the transaction, the insider owned 212,122 shares in the company, valued at $7,424,270. This trade represents a 8.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 60,000 shares of company stock worth $1,725,000 in the last three months. 4.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtus Advisers LLC bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at approximately $34,000. GAMMA Investing LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,628 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 75.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 1,308 shares in the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 883.3% in the second quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company's stock valued at $66,000 after purchasing an additional 3,763 shares in the last quarter. Finally, CWM LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 134.3% in the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 2,523 shares in the last quarter. Institutional investors own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.